Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sage Therapeutics, Inc. SAGE
$51.36
-$1.21 (-2.35%)
На 18:00, 12 мая 2023
+25.92%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3150652640.00000000
-
week52high
54.86
-
week52low
28.64
-
Revenue
7686000
-
P/E TTM
-5603
-
Beta
1.15397900
-
EPS
-9.22000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 12:30
Описание компании
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Perform | Market Perform | 11 июл 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 10 мая 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 04 мая 2022 г. |
| Berenberg | Hold | 31 мар 2022 г. | |
| Loop Capital | Hold | 01 ноя 2022 г. | |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
| HC Wainwright & Co. | Neutral | Neutral | 09 ноя 2022 г. |
| BMO Capital | Market Perform | Market Perform | 09 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 21 ноя 2022 г. |
| JP Morgan | Overweight | Overweight | 06 дек 2022 г. |
| Guggenheim | Neutral | Buy | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| IGUCHI KIMI | D | 5642 | 1600 | 09 янв 2023 г. |
| IGUCHI KIMI | A | 59624 | 1600 | 09 янв 2023 г. |
| Golumbeski George | A | 2108 | 2108 | 04 янв 2023 г. |
| PAUL STEVEN M | A | 2395 | 2395 | 04 янв 2023 г. |
| IGUCHI KIMI | D | 7242 | 1800 | 04 янв 2023 г. |
| IGUCHI KIMI | A | 58024 | 1800 | 04 янв 2023 г. |
| JONAS JEFFREY M | D | 57499 | 2501 | 03 янв 2023 г. |
| JONAS JEFFREY M | A | 118308 | 2501 | 03 янв 2023 г. |
| PAUL STEVEN M | A | 78539 | 5 | 28 ноя 2022 г. |
| Greene Barry E | A | 46940 | 14500 | 10 ноя 2022 г. |
Новостная лента
Sage Therapeutics to Present at Upcoming May Investor Conferences
Business Wire
03 мая 2023 г. в 06:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in May: BofA Securities 2023 Health Care Conference (Las Vegas, NV): presentation on Wednesday, May 10, 2023 at 2:20 p.m. PT. 2023 RBC Capital Markets Global Healthcare Conference (New York, NY): fireside chat on Wednesday, May 17, 2023 at 11:.
Sage Therapeutics, Inc. (SAGE) Q1 2023 Earnings Call Transcript
Seeking Alpha
02 мая 2023 г. в 15:28
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2023 Earnings Conference Call May 2, 2023 8:00 AM ET Company Participants Helen Rubinstein - Director of Investor Relations Barry Greene - Chief Executive Officer Jim Doherty - Chief Development Officer Chris Benecchi - Chief Business Officer Kimi Iguchi - Chief Financial Officer Laura Gault - Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Ritu Baral - PD Cowen Yasmeen Rahimi - Piper Sandler Jay Olson - Oppenheimer Paul Matteis - Stifel Sumant Kulkarni - Canaccord Neena Bitritto-Garg - Citi Tim Lugo - William Blair Marc Goodman - SVB Securities Operator Good morning. Welcome to the Sage Therapeutics' First Quarter 2023 Financial Results Conference Call.
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
02 мая 2023 г. в 09:08
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.46 per share versus the Zacks Consensus Estimate of a loss of $2.50. This compares to loss of $2.07 per share a year ago.
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
Business Wire
18 апр 2023 г. в 06:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 2, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com.
Sage Therapeutics to Present at the Stifel 2023 CNS Days
Business Wire
22 мар 2023 г. в 06:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 11:00 a.m. ET. A live webcast of the presentation can be accessed on the Investor page of Sage's website at investor.sagerx.com.